| __timestamp | Ligand Pharmaceuticals Incorporated | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 18516000 |
| Thursday, January 1, 2015 | 5807000 | 34140000 |
| Friday, January 1, 2016 | 5571000 | 51872000 |
| Sunday, January 1, 2017 | 5366000 | 71772000 |
| Monday, January 1, 2018 | 6337000 | 97501000 |
| Tuesday, January 1, 2019 | 11347000 | 118590000 |
| Wednesday, January 1, 2020 | 30419000 | 169802000 |
| Friday, January 1, 2021 | 62176000 | 7491000 |
| Saturday, January 1, 2022 | 52827000 | 8799000 |
| Sunday, January 1, 2023 | 35049000 | 253598000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Ligand Pharmaceuticals Incorporated and Xencor, Inc. over the past decade. From 2014 to 2023, Ligand Pharmaceuticals saw a significant increase in their cost of revenue, peaking in 2021 with a 580% rise from 2014. Meanwhile, Xencor, Inc. experienced a more volatile trajectory, with a staggering 1,270% increase in 2023 compared to 2014. Notably, Xencor's costs dipped in 2021, only to surge dramatically by 2023. These fluctuations highlight the dynamic nature of the pharmaceutical sector, where strategic investments and market conditions can significantly impact financial outcomes. As the industry continues to innovate, keeping an eye on these cost trends will be essential for making informed decisions.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Xencor, Inc.
Cost of Revenue Comparison: Xenon Pharmaceuticals Inc. vs Xencor, Inc.
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Xencor, Inc.
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.